Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

Indinavir (IDV) (also called CRIXIVAN, MK-639, or L-735,524) is a potent and selective inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease. During early clinical trials, in which patients initiated therapy with suboptimal dosages of IDV, we monitored the emergence of viral resistance to the inhibitor by genotypic and phenotypic characterization of primary HIV-1 isolates. Development of resistance coincided with variable patterns of multiple substitutions among at least 11 protease amino acid residues. No single substitution was present in all resistant isolates, indicating that resistance evolves through multiple genetic pathways. Despite this complexity, all of 29 resistant isolates tested exhibited alteration of residues M-46 (to I or L) and/or V-82 (to A, F, or T), suggesting that screening of these residues may be useful in predicting the emergence of resistance. We also extended our previous finding that IDV-resistant viral variants exhibit various patterns of cross-resistance to a diverse panel of HIV-1 protease inhibitors. Finally, we noted an association between the number of protease amino acid substitutions and the observed level of IDV resistance. No single substitution or pair of substitutions tested gave rise to measurable viral resistance to IDV. The evolution of this resistance was found to be cumulative, indicating the need for ongoing viral replication in this process. These observations strongly suggest that therapy should be initiated with the most efficacious regimen available, both to suppress viral spread and to inhibit the replication that is required for the evolution of resistance.

[1]  Rupert G. Miller.  The jackknife-a review , 1974 .

[2]  Frederick Mosteller,et al.  Data Analysis and Regression , 1978 .

[3]  F. Mosteller,et al.  Data Analysis and Regression , 1978 .

[4]  H. Gendelman,et al.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.

[5]  B. Holland,et al.  An Improved Sequentially Rejective Bonferroni Test Procedure , 1987 .

[6]  Gilcher Ro.  Human retroviruses and AIDS. , 1988 .

[7]  R. Gilcher.  Human retroviruses and AIDS. , 1988, The Journal of the Oklahoma State Medical Association.

[8]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J S Mills,et al.  Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. , 1991, Antiviral research.

[10]  Michael S. Saag,et al.  A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1993 .

[11]  J. Craig,et al.  In vitro Resistance to an Inhibitor of HIV Proteinase (Ro 31-8959) Relative to Inhibitors of Reverse Transcriptase (AZT and TIBO) , 1993 .

[12]  J. Condra,et al.  Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors , 1993, Antimicrobial Agents and Chemotherapy.

[13]  O. Turriziani,et al.  In vitro Selection of Human Immunodeficiency Virus Type 1 Resistant to Ro 31-8959 Proteinase Inhibitor , 1993 .

[14]  P. Darke,et al.  L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. , 1994, Journal of medicinal chemistry.

[15]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Y. Wong,et al.  A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs , 1994, Biopharmaceutics & drug disposition.

[17]  O. Turriziani,et al.  Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. , 1994, Acta virologica.

[18]  L. Everitt,et al.  Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D Norbeck,et al.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.

[20]  M. Kuroda,et al.  Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor , 1994, Journal of virology.

[21]  D. Ho,et al.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.

[22]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[23]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Barrish,et al.  Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor , 1995, Journal of virology.

[25]  R. Myers,et al.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease , 1995, Journal of virology.

[26]  L. Bacheler,et al.  Multiple Mutations in the Human Immunodeficiency Virus Protease Gene Are Responsible for Decreased Susceptibility to Protease Inhibitors , 1995 .

[27]  E D Blair,et al.  Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors , 1995, Antimicrobial agents and chemotherapy.

[28]  I B Duncan,et al.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.

[29]  G. Decrescenzo,et al.  SC-52151, a novel inhibitor of the human immunodeficiency virus protease , 1995, Antimicrobial agents and chemotherapy.

[30]  H. Nitschko,et al.  Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. , 1995, AIDS research and human retroviruses.

[31]  M. Murcko,et al.  Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .

[32]  E. De Clercq,et al.  Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538) , 1996, AIDS.

[33]  M. Ott,et al.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. , 1996, The Journal of infectious diseases.

[34]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[35]  Bradley Efron,et al.  The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients , 1996, Annals of Internal Medicine.

[36]  B. Korber,et al.  Human retroviruses and AIDS 1997 , 1997 .